CollPlant Biotechnologies Business Summary

CollPlant Biotechnologies Ltd (CLGN) is a regenerative and aesthetic medicine company that generates revenue through a hybrid model of direct product sales, strategic licensing, and milestone-based development agreements. The company’s operations are concentrated in three primary segments: 3D Bioprinting (BioInk), Medical Aesthetics (dermal fillers), and Tissue Repair (VergenixSTR). Revenue is primarily driven by the commercialization of its proprietary recombinant human Type I collagen (rhCollagen), produced via plant-based genetic engineering, and high-value partnerships, most notably a global commercialization agreement with AbbVie’s Allergan Aesthetics. In the competitive landscape, CollPlant contends with industry players such as Revance Therapeutics, Evolus, MiMedx Group, and Axial3D. While many competitors rely on animal-derived or synthetic materials, CollPlant differentiates itself as the only provider of commercially viable, plant-derived rhCollagen, positioning it as a critical upstream supplier for the next generation of biofabrication and regenerative implants. The company was founded by Professor Oded Shoseyov, a distinguished scientist from the Hebrew University of Jerusalem with over 90 patents in plant biotechnology, who currently serves as Chief Scientist and CTO. The executive leadership is headed by CEO and Interim Chairman Yehiel Tal, who brings over 25 years of management experience in the Israeli and American biotech sectors, alongside Deputy CEO and CFO Eran Rotem, a veteran financial executive. Other key leadership figures include VP of Operations Oren Fahimipoor and VP of Human Resources Hadas Dreiher-Horowitz. The board of directors features high-pedigree members such as Hugh Evans, a former executive at 3D Systems, and Alisa Lask, a former VP at Galderma and Allergan. CollPlant has secured backing from prominent institutional investors including Pontifax and Invesco, underscoring its strategic role at the intersection of 3D printing and advanced regenerative medicine.